ABBV AbbVie Inc.

86.37
+1.05  (1%)
Previous Close 85.32
Open 85.54
Price To book 22.91
Market Cap 137681959066
Shares 1,594,094,698
Volume 7,570,863
Short Ratio 4.75
Av. Daily Volume 6,054,800

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-414
Recurrent glioblastoma (rGBM)
Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths.
ABT-494 - SELECT-BEYOND
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
ABBV-8E12
Alzheimer's disease
Phase 3 interim data possibly due 2H 2017.
Imbruvica - PHOENIX
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 data released September 18, 2017 - PFS primary endpoint met.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 trial initiated July 2016. Data due 2019.
Venetoclax
Relapsed or refractory multiple myeloma
Phase 3 trial to commence 2017.
Venclexta
Follicular lymphoma (FL)
Phase 3 trial to commence 2017.
Venclexta
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial to commence 2017.
Rova-T
First-line small cell lung cancer (SCLC) maintenance
Phase 3 trial to commence 1H 2017.
Risankizumab
Crohn’s Disease
Phase 3 data due by the end of 2017.
Risankizumab
Psoriasis
Phase 3 initiated in January 2016. Data due late 2017.
Elagolix
Uterine Fibroids
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017.
Elagolix
Endometriosis
Phase 3 trial to commence 2017.
ABT-494
Psoriatic Arthritis
Phase 3 top-line data released June 7, 2017 - primary endpoints met.
ABT-494 (upadacitinib) - SELECT-NEXT
Rheumatoid arthritis
Phase 2b data due 2017.
Risankizumab
Psoriatic Arthritis
Phase 2 positive data at DDW Meeting May 9, 2017. Phase 3 trial to be initiated later in 2017.
ABT-494
Crohn’s Disease
Phase 2 pivotal data due 2017.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2b data released September 7, 2017 - primary endpoint met.
ABT-494
Atopic Dermatitis
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)

Latest News

  1. Roche (RHHBY) Announces Positive Data on Leukemia Drug
  2. 3 Value Stocks at 52-Week Highs Still Worth Buying
  3. 3 High-Yield Pharmaceutical Stocks
  4. AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
  5. J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU
  6. Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
  7. AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share
  8. Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx
  9. How Safe Is Abbott Labs' Dividend?
  10. See what the IHS Markit Score report has to say about AbbVie Inc.
  11. Cramer's lightning round: Here's where Qualcomm went wron...
  12. Cramer's lightning round: Here's where Qualcomm went wrong
  13. AbbVie Is Likely to Correct: Book Some Profits
  14. Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data
  15. Today's Research Reports on Trending Tickers: AbbVie and Intercept Pharmaceuticals
  16. 5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing
  17. AbbVie's RA Candidate Meets Primary Endpoint in Phase III
  18. These 3 Stocks Have Lifted Vanguard High Dividend Yield ETF in 2017
  19. 5 Things Regeneron's CEO Said as the Biotech Stock Sank